Patrick Zweidler-McKay
Chief Medical Officer NEOK Bio
Seminars
Tuesday 13th October 2026
The Emerging Wave of Bispecific ADCs: Breaking Down Design & Rationale for NEOK001 & NEOK002
12:00 pm
- Delving into the IND enabling profiles of bispecific ADCs NEOK001 and 002, emphasizing advantages over monospecific ADCs
- Explaining the unique characteristics of NEOK001 targeting B7-H3+ROR1 including higher need for differentiation amongst B7-H3 ADC landscape
- Breaking down early clinical development strategy and lessons learned from ongoing Phase I bispecific ADC trials
Tuesday 13th October 2026
Innovating Antibody Targeting & Engineering to Improve ADC Therapeutic Properties & Unlock New Treatment Indications
Thursday 15th October 2026
Breaking Down Trends & Strategies to Maximize ADC Clinical Impact in an Increasingly Busy Oncology Landscape
1:00 pm
With more ADCs entering the clinic than ever before, it has never been more important to optimize clinical strategies to demonstrate differentiation and benefit oncology patients.
Attend this session to follow ADC clinical trends across development phases from early to late-stage, and contextualize evolving strategies to stand out from the crowd and maximize differentiation opportunity in crowded oncology indications.
Workshop highlights include:
- Breaking down the ADC clinical development trends in an increasingly busy oncology treatment landscape: How will ADCs fit into future patient therapy regiments?
- Evolving strategies to unlock clinical benefit across combination and sequencing approaches as more ADCs are approved, particularly into front-line patient therapies
- Finding the right patient for the right ADC: Evaluating when and how to implement patient cut-off criteria
